Drug intelligence / Profile preview

anti-BKV mAbs

Development stage: Preclinical
Lead developer: IDBiologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

anti-BKV mAbs is a therapeutic program being developed by IDBiologics consisting of monoclonal antibodies designed to neutralize the BK virus (BKV). The primary goal of this program is to prevent and treat BKV viremia and BKV-associated nephropathy (BKVAN) in kidney transplant recipients. BKV is a polyomavirus that often reactivates in the setting of therapeutic immunosuppression, leading to significant morbidity and potential loss of the renal graft. These antibodies work by binding to the virus and blocking its ability to infect host cells, thereby controlling viral replication and preserving kidney function.

Other names: BK virus monoclonal antibodiesBKV-neutralizing monoclonal antibodies

Targets

Norovirus VP1

Beyond the preview

Go deeper on anti-BKV mAbs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-BKV mAbs.

Explore the full profile